Companies / Fate Therapeutics Inc

Fate Therapeutics Inc

Nasdaq: FATECIK 1434316SAN DIEGO, CAfatetherapeutics.com ↗

Financials · FY2025

Revenue$6.65M
Net income$-136.31M
Total debt$9.47M
Cash$32.43M
Diluted EPS$-1.15
Shares outstanding119.8M

Ownership

119.8M shares outstanding · as of Aug 6, 2026
1.1%Insiders
Ownership
Insiders1.11%1,324,451
Institutions60.06%71,965,418
Public float38.83%46,530,645

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 5

View all →
Insider% of sharesShares
Valamehr BahramCEOPresident and CEO · Director
0.55%664,708
Tahl CindySee Remarks
0.41%487,081
Adawi KamalChief Financial Officer
0.08%100,000
Epstein Robert SDirector
0.03%36,331
Rastetter William HDirector
0.03%36,331

Institutional holders 146

View all →
HolderValue% of shares
BlackRock, Inc.$19.71M6.09%
Redmile Group, LLC$12.65M10.74%
Vanguard Group Inc$8.82M7.49%
Two Sigma Investments, LP$4.16M2.89%
AQR Capital Management, LLC$3.60M2.51%
Renaissance Technologies LLC$3.57M2.48%
Johnson & Johnson$3.32M2.82%
Geode Capital Management, LLC$3.11M2.16%
Vestal Point Capital, LP$1.69M1.44%
Two Sigma Advisers, LP$1.62M1.38%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
May 5, 2026Epstein Robert S
Director
ExerciseCommon Stock$42.3K+25K
+220.63%
36,331
0.03% of shares
low
May 5, 2026Rastetter William H
Director
ExerciseCommon Stock$42.3K+25K
+220.63%
36,331
0.03% of shares
low
Jan 9, 2026Tahl Cindy
Executive
SellCommon Stock$11.3K-11K
-2.66%
387,081
0.32% of shares
low
Jan 9, 2026Valamehr Bahram
CEO
SellCommon Stock$5.6K-5K
-1.55%
329,708
0.28% of shares
low
Jan 15, 2026Adawi Kamal
Executive
GrantCommon Stock$0+25K
+33.33%
100,000
0.08% of shares
low
Jan 15, 2026Valamehr Bahram
CEO
GrantCommon Stock$0+335K
+101.61%
664,708
0.55% of shares
low
Jan 15, 2026Tahl Cindy
Executive
GrantCommon Stock$0+100K
+25.83%
487,081
0.41% of shares
low
Jun 12, 2026Epstein Robert S
Director
GrantStock Option (Right to Buy)—+88K
87,900
0.07% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A—0—

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
FATE——31189P102—